Retrospective evaluation of lymphatic and blood vessel invasion and Borrmann types in advanced proximal gastric cancer

Gao, Shan; Cao, Guohui; Ding, Peng; Zhao, Yangyang; Deng, Peng; Hou, Bin; Li, Kai; Liu, Xiaofang

doi:10.4251/wjgo.v11.i8.642

Cited by 10 publications

(7 citation statements)

References 22 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Yamashita et al [ 23 ] considered that for patients with pTNM stage II/III, giant Borrmann type III AGC (≥8 cm) had similar sensitivity to postoperative adjuvant chemotherapy with Borrmann type IV AGC; Both belonged to the high-risk macroscopic type, and the 5-year survival rate was 35.7%. However, other studies found that patients with vascular infiltration Borrmann type III had the same poor prognosis as type IV, with a 5-year survival rate of 16.4%–19.4% [ 8 , 24 ]. The reason for this divergence is the high heterogeneity of GC.…”

Section: Discussionmentioning

confidence: 99%

Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer

et al. 2022

View full text Add to dashboard Cite

Background The prognosis of Borrmann type III advanced gastric cancer (AGC) is known to vary significantly among patients. This study aimed to determine which differentially expressed genes (DEGs) are directly related to the survival time of Borrmann type III AGC patients and to construct a prognostic model. Methods We selected 25 patients with Borrmann type III AGC who underwent radical gastrectomy. According to the difference in overall survival (OS), the patients were divided into group A (OS<1 year, n=11) and group B (OS>3 years, n=14). DEGs related to survival time in patients with Borrmann type III AGC were determined by mRNA sequencing. The prognosis and functional differences of DEGs in different populations were determined by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) public databases. The expression of mRNA and protein in cell lines was detected by quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) and Western blot (WB). Immunohistochemical (IHC) staining was used to detect protein expression in the paraffin-embedded tissues of 152 patients with Borrmann type III AGC who underwent radical gastrectomy. After survival analysis, nomograms were constructed to predict the prognosis of patients with Borrmann type III AGC. Results Arylacetamide deacetylase (AADAC) is a survival-related DEG in patients with Borrmann type III AGC. The higher the expression level of its mRNA and protein is, the better the prognosis of patients. Bioinformatics analysis found that AADAC showed significant differences in prognosis and function in European and American populations and Asian populations. In addition, the mRNA and protein expression levels of AADAC were high in differentiated gastric cancer (GC) cells. We also found that AADAC was an independent prognostic factor for patients with Borrmann type III AGC, and its high expression was significantly correlated with better OS and disease-free survival (DFS). Nomogram models of AADAC expression level combined with clinicopathological features can be used to predict the OS and DFS of Borrmann type III AGC. Conclusion AADAC can be used as a biomarker to predict the prognosis of Borrmann type III AGC and has the potential to become a new therapeutic target for GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since proximal GC has more aggressive biological characteristics than distal GC, the prognosis of proximal GC is worse than that of distant GC[ 20 - 22 ]. The study by Gao et al[ 23 ] showed that in proximal GC, there is no significant difference in prognosis between patients with Borrmann type III disease and LBVI (+) and those with Borrmann type IV and LBVI (-). This is similar to the results of this study, which also included patients with GC in various locations.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of Borrmann type combined with vessel invasion status in advanced gastric cancer

Zhai¹,

Zhu²,

Zhang³

et al. 2020

WJGO

View full text Add to dashboard Cite

BACKGROUND Borrmann classification (types I-IV) for the detection of advanced gastric cancer has been accepted worldwide, and lymphatic and/or blood vessel invasion (LBVI) status is related to the poor prognosis after gastric cancer. AIM To evaluate the significance of Borrmann type combined with LBVI status in predicting the prognosis of advanced gastric cancer. METHODS We retrospectively studied the clinicopathological characteristics and long-term survival data of 2604 patients who were diagnosed with advanced gastric adenocarcinoma at Harbin Medical University Cancer Hospital from January 2009 to December 2013. Categorical variables were evaluated by the Pearson’s χ 2 test, the Kaplan-Meier method was used to identify differences in cumulative survival rates, and the Cox proportional hazards model was used for multivariate prognostic analysis. RESULTS A total of 2604 patients were included in this study. The presence of LVBI [LBVI (+)] and Borrmann type ( P = 0.001), tumor location ( P < 0.001), tumor size ( P < 0.001), histological type ( P < 0.001), tumor invasion depth ( P < 0.001), number of metastatic lymph nodes ( P < 0.001), and surgical method ( P < 0.001) were significantly correlated with survival. When analyzing the combination of the Borrmann classification and LBVI status, we found that patients with Borrmann type III disease and LBVI (+) had a similar 5-year survival rate to those with Borrmann IV + LBVI (-) (16.4% vs 13.1%, P = 0.065) and those with Borrmann IV + LBVI (+) (16.4% vs 11.2%, P = 0.112). Subgroup analysis showed that the above results were true for any pT stage and any tumor location. Multivariate Cox regression analysis showed that Borrmann classification ( P = 0.023), vascular infiltration ( P < 0.001), tumor size ( P = 0.012), pT stage ( P < 0.001), pN stage ( P < 0.001), and extent of radical surgery ( P < 0.001) were independent prognostic factors for survival. CONCLUSION Since patients with Borrmann III disease and LBVI (+) have the same poor prognosis as those with Borrmann IV disease, more attention should be paid to patients with Borrmann III disease and LBVI (+) during diagnosis and treatment, regardless of the pT stage and tumor location, to obtain better survival results.

show abstract

“…When assessing LVI, it is important to exclude false-positive and false-negative cases of LVI, which is possible when using the immunohistochemical method of staining tumor tissue[ 171 ]. In a group of patients with LVI+/perineural invasion (PNI)+, the overall and relapse-free survival rates were significantly lower than in the group of patients who were LVI-/PNI-[ 137 - 140 ], including in patients with lymph node-negative GC[ 141 , 142 ] and in patients who received neoadjuvant chemotherapy[ 172 ]. Interestingly, adjuvant chemotherapy significantly improved overall and disease-free survival in PNI+ but not PNI- patients, and these results were not influenced by disease stage[ 173 ].…”

Section: Results Of Angiogenesis Activity Assessment In Gcmentioning

confidence: 99%

Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer

Сеньчукова¹

2021

WJG

View full text Add to dashboard Cite

Gastric cancer (GC) remains a serious oncological problem, ranking third in the structure of mortality from malignant neoplasms. Improving treatment outcomes for this pathology largely depends on understanding the pathogenesis and biological characteristics of GC, including the identification and characterization of diagnostic, prognostic, predictive, and therapeutic biomarkers. It is known that the main cause of death from malignant neoplasms and GC, in particular, is tumor metastasis. Given that angiogenesis is a critical process for tumor growth and metastasis, it is now considered an important marker of disease prognosis and sensitivity to anticancer therapy. In the presented review, modern concepts of the mechanisms of tumor vessel formation and the peculiarities of their morphology are considered; data on numerous factors influencing the formation of tumor microvessels and their role in GC progression are summarized; and various approaches to the classification of tumor vessels, as well as the methods for assessing angiogenesis activity in a tumor, are highlighted. Here, results from studies on the prognostic and predictive significance of tumor microvessels in GC are also discussed, and a new classification of tumor microvessels in GC, based on their morphology and clinical significance, is proposed for consideration.

show abstract

Retrospective evaluation of lymphatic and blood vessel invasion and Borrmann types in advanced proximal gastric cancer

Cited by 10 publications

References 22 publications

Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer

Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer

Prognostic significance of Borrmann type combined with vessel invasion status in advanced gastric cancer

Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer

Contact Info

Product

Resources

About